Literature DB >> 15660233

Development of multiple malignancies after immunosuppression in a patient with Wegener's granulomatosis.

Mari Hoff1, Erik Rødevand.   

Abstract

We describe the development of multiple malignancies in a patient with Wegener's granulomatosis treated with glucocorticosteroids, azathioprin and cyclophosphamide over 20 years. His symptoms started with a neurological disease, which is unusual. Less attention was paid to other symptoms that occurred simultaneously and were more typical manifestations of the disease. This resulted in delayed diagnosis. Despite incorrect diagnoses, he received appropriate immunosuppressive therapy. After 2 years of therapy, he developed a spinocellular carcinoma, after 12 years a basal cell carcinoma and after 19 years both a Kaposi sarcoma and a urinary bladder carcinoma. This patient illustrates a difficult therapeutic balance between prolonged treatment and the hazards of therapy. No guidelines are established to manage this clinical dilemma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15660233     DOI: 10.1007/s00296-004-0551-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  14 in total

Review 1.  New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis.

Authors:  Caroline O S Savage; Lorraine Harper; Mark Holland
Journal:  Curr Opin Rheumatol       Date:  2002-01       Impact factor: 5.006

2.  Nasal cavity squamous cell carcinoma in Wegener's granulomatosis.

Authors:  J Stein; S T Sridharan; I Eliachar; A Niv; B Wood; G S Hoffman
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2001-06

3.  Kaposi's sarcoma in an elderly man with Wegener's granulomatosis treated with cyclophosphamide and corticosteroids.

Authors:  S B Erban; R K Sokas
Journal:  Arch Intern Med       Date:  1988-05

4.  Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis.

Authors:  T J Stillwell; R C Benson; R A DeRemee; T J McDonald; L H Weiland
Journal:  Arthritis Rheum       Date:  1988-04

5.  Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement.

Authors:  K W Westman; P G Bygren; H Olsson; J Ranstam; J Wieslander
Journal:  J Am Soc Nephrol       Date:  1998-05       Impact factor: 10.121

6.  Cyclophosphamide cystitis--identification of acrolein as the causative agent.

Authors:  P J Cox
Journal:  Biochem Pharmacol       Date:  1979-07-01       Impact factor: 5.858

7.  An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

Authors:  E Reinhold-Keller; N Beuge; U Latza; K de Groot; H Rudert; B Nölle; M Heller; W L Gross
Journal:  Arthritis Rheum       Date:  2000-05

Review 8.  Malignancies associated with the immunocompromised state.

Authors:  K Katariya; R J Thurer
Journal:  Chest Surg Clin N Am       Date:  1999-02

9.  Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens.

Authors:  P Jensen; S Hansen; B Møller; T Leivestad; P Pfeffer; O Geiran; P Fauchald; S Simonsen
Journal:  J Am Acad Dermatol       Date:  1999-02       Impact factor: 11.527

10.  Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.

Authors:  C Talar-Williams; Y M Hijazi; M M Walther; W M Linehan; C W Hallahan; I Lubensky; G S Kerr; G S Hoffman; A S Fauci; M C Sneller
Journal:  Ann Intern Med       Date:  1996-03-01       Impact factor: 25.391

View more
  5 in total

1.  Kaposi's sarcoma concurrent with granulomatosis polyangiitis.

Authors:  Diler Taş Kılıç; Selma Karaahmetoğlu Özkan; Başol Canbakan; Nesrin Dündar
Journal:  Eur J Rheumatol       Date:  2015-08-21

2.  [Remission of an iatrogenic Kaposi sarcoma in a patient with myasthenia gravis after switching immunosuppressive therapy to the mTOR inhibitor everolimus].

Authors:  S Krengel; I Satzger; M Alter; A Kapp; R Gutzmer
Journal:  Hautarzt       Date:  2012-07       Impact factor: 0.751

3.  Kaposi sarcoma in an patient with atopic dermatitis treated with ciclosporin.

Authors:  Dmitri Wall; Mairín McMenamin; Deirdre O'Mahony; Alan D Irvine
Journal:  BMJ Case Rep       Date:  2013-11-21

Review 4.  Kaposi sarcoma in anti-neutrophil cytoplasmic antibody-associated vasculitis: a case-based review.

Authors:  Benedict K Tiong; Arun S Singh; G Peter Sarantopoulos; Tanaz A Kermani
Journal:  Rheumatol Int       Date:  2021-02-23       Impact factor: 2.631

5.  Iatrogenic Kaposi's sarcoma after immunosuppressive treatment for granulomatosis with polyangiitis (Wegener's).

Authors:  Anjali Saxena; Elena Netchiporouk; Raqiya Al-Rajaibi; Robin Billick; Osama Roshdy
Journal:  JAAD Case Rep       Date:  2015-03-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.